BGB-283

DRUG2 trials

Sponsors

BeiGene

Conditions

Solid Tumors

Phase 1

Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors

CompletedNCT02610361

BeiGeneSolid Tumors

Start: 2013-11-20End: 2017-10-31Updated: 2024-12-27

The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor

CompletedNCT03641586

BeiGeneSolid Tumors

Start: 2015-10-12End: 2019-03-07Updated: 2024-10-23